Press Releases - Ulrich Betz.

concernedimpartialBiotechnology

Dec 3, 2012 (4 years and 4 months ago)

207 views

Press Releases

Molecular Sensing, Inc. Enters into Agreement with Merck KGaA for
Access to Novel Molecular Interaction Technology

Montara, California, June 9, 2008

-

Mol ecul ar Sensi ng, Inc.
(MSI) today
announced that i t has entered i nto an extensi ve Li fe
Sci ence Earl y Access
Program (LEAP) agreement wi th Merck KGaA, Darmstadt, Germany, acti ng on
behal f of i ts di vi si on for i nnovati ve prescri pti on pharmaceuti cal s, Merck
Serono, to eval uate propri etary MSI Back
-
Scatteri ng Interferometry (BSI)
technol ogy. The
cooperati on wi l l eval uate BSI technol ogy and MSI
i nstrumentati on rel ated to drug di scovery, devel opment, and research
appl i cati ons. Fi nanci al detai l s were not di scl osed.

As reported by Bornhop, et al., i n
Science

(September 2007), BSI technol ogy
uni quel y e
nabl es homogeneous assays of mol ecul ar i nteracti ons at zeptomol e
sensi ti vi ty. Measurements are made i n sol uti on to determi ne affi ni ty
constants between associ ati ng mol ecul es, free of coupl i ng to spectroscopi c
l abel s or tetheri ng to a chi p surface.

BSI val i
dated assays i ncl ude protei n bi ndi ng to metal i ons, drugs, pepti des,
or other protei ns, anti gen
-
anti body associ ati on, and DNA
-
protei n or DNA
-
DNA
bi ndi ng, i n serum, cel l l ysates, and cel l free medi a wi th mi crol i ter sampl e
vol ume and pi comol ar sensi ti vi ty.

"BSI i s a breakthrough i n mol ecul ar i nteracti on assay technol ogy," sai d Scot
Wei nberger, MSI's Presi dent and Chi ef Executi ve Offi cer. "We are pl eased to
work wi th Merck Serono, a l eader i n pharmaceuti cal s compri si ng bi ol ogi cs
and drugs, to i nvesti gate the
potenti al benefi ts that BSI technol ogy and MSI
products can bri ng to thei r pharmaceuti cal di scovery, research, and
devel opment programs."

About Molecular Sensing

Mol ecul ar Sensi ng, Inc. i s an earl y stage bi otechnol ogy company, l ocated i n
the San Franci sco
Bay area, dedi cated to the creati on of mol ecul ar
i nteracti on i nstrumentati on and appl i cati ons that enabl e homogeneous i n
vi tro bi ochemi cal and cel l
-
based assays, that are l abel
-
free and tether
-
free,
usi ng ki neti c and end
-
poi nt anal ysi s. Its i ni ti al market
focus i s i n academi c,
government, di agnosti c and pharmaceuti cal l aboratori es.

MSI's Li fe Sci ence Earl y Access Program (LEAP) i s a fee
-
based earl y access
program desi gned to provi de customi zed col l aborati on partnershi ps wi th
major l aboratori es i n basi c l i fe

sci ences and/or transl ati onal research, cl i ni cal
di agnosti cs, and pharmaceuti cal R&D. LEAP col l aborati ons are i ntended to
hel p MSI devel op and val i date enabl i ng appl i cati ons as wel l as to advance
the devel opment of i ts i nstrumentati on.

Mol ecul ar Sensi ng,
Inc. Contacts:

LEAP Partnershi ps: 650
-
728
-
8110,
EAP@mol sense.com

Investors: Scot Wei nberger, 650
-
728
-
8111,
swei nberger@mol sense.com